EGFR and non-small cell lung carcinoma: To the best of our knowledge, this is the first real‐world study to report an overall survival benefit of an irreversible EGFR‐TKI compared to reversible EGFR‐TKIs in patients with advanced stage EGFR‐mutant NSCLC without BM.